Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of lenvatinib mesylate when given
together with paclitaxel in treating patients with endometrial, ovarian, fallopian tube, or
primary peritoneal cancer that has come back or grown. Lenvatinib mesylate may stop the
growth of tumor cells by blocking a protein needed for cell growth and may block the growth
of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as
paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving lenvatinib
mesylate and paclitaxel together may work better in treating patients with endometrial,
ovarian, fallopian tube, or primary peritoneal cancer.